BrickBio Enters into Antibody Drug Conjugate (ADC) Co-Development Partnership with a Large Pharmaceutical Company
Share this article Share this article BOSTON, Jan. 6, 2021 /PRNewswire/ -- BrickBio, the leading company in site-specific bioconjugation for improved therapeutics, has signed a deal with a large pharmaceutical partner to co-develop a therapeutic antibody drug conjugate (ADC). Financials and the split of therapeutic intellectual property were not disclosed. BrickBio has a focused effort in the areas of oncology, neurology, and metabolic disease, although the company's established site-specific modification process is robust and expandable beyond the scope of these disease states. In addition...
Source: prnewswire.com